{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:22:00Z","timestamp":1794320520150,"version":"4.9.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Provincial Key Research and Development Program of Heilongjiang Province","award":["GA21C001"],"award-info":[{"award-number":["GA21C001"]}]},{"name":"Distinguished Young Scientist Funding of Harbin Medical University Affiliated Tumor Hospital","award":["JCQN2019-02"],"award-info":[{"award-number":["JCQN2019-02"]}]},{"name":"Key Project of Harbin Medical University Cancer Hospital Climbing Funding","award":["PDYS2024-03"],"award-info":[{"award-number":["PDYS2024-03"]}]},{"name":"Key Innovation Technology Project Harbin Medical University Cancer (Hospital Innovation Technology Funding","award":["CXJSZD-2023-04)"],"award-info":[{"award-number":["CXJSZD-2023-04)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00259-024-07007-y","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T02:22:18Z","timestamp":1734315738000},"page":"1354-1369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial"],"prefix":"10.1007","volume":"52","author":[{"given":"Liping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiyasi","family":"Nanding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"7007_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","volume":"38","author":"S Pastorekova","year":"2019","unstructured":"Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38:65\u201377. https:\/\/doi.org\/10.1007\/s10555-019-09799-0.","journal-title":"Cancer Metastasis Rev"},{"key":"7007_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.eururo.2012.08.024","volume":"64","author":"AB Stillebroer","year":"2013","unstructured":"Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013;64:478\u201385. https:\/\/doi.org\/10.1016\/j.eururo.2012.08.024.","journal-title":"Eur Urol"},{"key":"7007_CR3","first-page":"2729","volume":"4","author":"CR Divgi","year":"1998","unstructured":"Divgi CR, Bander NH, Scott AM, O\u2019Donoghue JA, Sgouros G, Welt S, et al. Phase I\/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729\u201339.","journal-title":"Clin Cancer Res"},{"key":"7007_CR4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.eururo.2013.02.022","volume":"63","author":"CH Muselaers","year":"2013","unstructured":"Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013;63:1101\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2013.02.022.","journal-title":"Eur Urol"},{"key":"7007_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2967\/jnumed.110.083295","volume":"52","author":"DA Pryma","year":"2011","unstructured":"Pryma DA, O\u2019Donoghue JA, Humm JL, Jungbluth AA, Old LJ, Larson SM, et al. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med. 2011;52:535\u201340. https:\/\/doi.org\/10.2967\/jnumed.110.083295.","journal-title":"J Nucl Med"},{"key":"7007_CR6","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.2174\/0929867329666220607160559","volume":"29","author":"R Sharma","year":"2022","unstructured":"Sharma R, Suman SK, Mukherjee A. Antibody-based Radiopharmaceuticals as Theragnostic agents: an overview. Curr Med Chem. 2022;29:5979\u20136005. https:\/\/doi.org\/10.2174\/0929867329666220607160559.","journal-title":"Curr Med Chem"},{"key":"7007_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00261-015-0599-1","volume":"41","author":"B Turkbey","year":"2016","unstructured":"Turkbey B, Lindenberg ML, Adler S, Kurdziel KA, McKinney YL, Weaver J, et al. PET\/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study. Abdom Radiol (NY). 2016;41:109\u201318. https:\/\/doi.org\/10.1007\/s00261-015-0599-1.","journal-title":"Abdom Radiol (NY)"},{"key":"7007_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2967\/jnumed.115","volume":"57","author":"N Krall","year":"2016","unstructured":"Krall N, Pretto F, Mattarella M, M\u00fcller C, Neri D. A 99mTc-Labeled ligand of Carbonic anhydrase IX selectively targets renal cell carcinoma in vivo. J Nucl Med. 2016;57:943\u20139. https:\/\/doi.org\/10.2967\/jnumed.115170514.","journal-title":"J Nucl Med"},{"key":"7007_CR9","doi-asserted-by":"publisher","unstructured":"Krall N, Pretto F, Mattarella M, M\u00fcller C, Neri D. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo. J Nucl Med. 2016; 57:943-9. https:\/\/doi.org\/10.2967\/jnumed.115170514.","DOI":"10.2967\/jnumed.115170514"},{"key":"7007_CR10","doi-asserted-by":"publisher","unstructured":"Zhu W, Li X, Zheng G, Bai C, Ji Z, Zhang H, et al. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2023; 50:3116\u20133125. https:\/\/doi.org\/10.1007\/s00259-023-06248-7.","DOI":"10.1007\/s00259-023-06248-7"},{"key":"7007_CR11","doi-asserted-by":"publisher","unstructured":"Cri\u0219an G, Moldovean-Cioroianu NS, Timaru DG, Andrie\u0219 G, C\u0103inap C, Chi\u0219 V. Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. Int J Mol Sci.2022; 23:5023. https:\/\/doi.org\/10.3390\/ijms23095023.","DOI":"10.3390\/ijms23095023"},{"key":"7007_CR12","doi-asserted-by":"publisher","unstructured":"Scarpulla V, Amadasi A, Pelotti S, Ingravallo F. Applicability and usefulness of the Declaration of Helsinki for forensic research with human cadavers and remains.Forensic Sci Med Pathol. 2023; 19:1\u20137. https:\/\/doi.org\/10.1007\/s12024-022-00510-4.","DOI":"10.1007\/s12024-022-00510-4"},{"key":"7007_CR13","doi-asserted-by":"publisher","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021; 112:90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"7007_CR14","doi-asserted-by":"publisher","unstructured":"Garousi J, Huizing FJ, Vorobyeva A, Mitran B, Andersson KG, Leitao CD, et al.Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. Sci Rep. 2019; 9:14907. https:\/\/doi.org\/10.1038\/s41598-019-51445-w.","DOI":"10.1038\/s41598-019-51445-w"},{"key":"7007_CR15","doi-asserted-by":"publisher","unstructured":"He C, Liu F, Tao J, Wang Z, Liu J, Liu S, et al. A CAIX Dual-Targeting Small-Molecule Probe for Noninvasive Imaging of ccRCC. Mol Pharm. 2024; 21:3383\u20133394. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00104.","DOI":"10.1021\/acs.molpharmaceut.4c00104"},{"key":"7007_CR16","doi-asserted-by":"publisher","unstructured":"van Oostenbrugge T, Mulders P. Targeted PET\/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab. Curr Opin Urol. 2021; 31:249\u2013254. https:\/\/doi.org\/10.1097\/MOU.0000000000000872.","DOI":"10.1097\/MOU.0000000000000872"},{"key":"7007_CR17","doi-asserted-by":"publisher","unstructured":"Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E,et al. Positron Emission Tomography\/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. Eur Urol. 2018; 74:257\u2013260. https:\/\/doi.org\/10.1016\/j.eururo.2018.04.026.","DOI":"10.1016\/j.eururo.2018.04.026"},{"key":"7007_CR18","doi-asserted-by":"publisher","unstructured":"Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, et al. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019; 46:1931\u20131939. https:\/\/doi.org\/10.1007\/s00259-019-04358-9.","DOI":"10.1007\/s00259-019-04358-9"},{"key":"7007_CR19","doi-asserted-by":"publisher","unstructured":"Hofman MS, Tran B, Feldman DR, Pokorska-Bocci A, Pichereau S, Wessen J, et al.First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma. J Nucl Med. 2024 22; 65:740\u20133. https:\/\/doi.org\/10.2967\/jnumed.123.267175.","DOI":"10.2967\/jnumed.123.267175"},{"key":"7007_CR20","doi-asserted-by":"publisher","unstructured":"Ma H, \u00d3\u2019F\u00e1g\u00e1in C, O\u2019Kennedy R. Antibody stability: A key to performance - Analysis,influences and improvement. Biochimie. 2020; 177:213\u2013225. https:\/\/doi.org\/10.1016\/j.biochi.2020.08.019.","DOI":"10.1016\/j.biochi.2020.08.019"},{"key":"7007_CR21","doi-asserted-by":"publisher","unstructured":"Decristoforo C, Pickett RD, Verbruggen A. Feasibility and availability of \u2076\u2078Ga-labelled peptides. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1: S31-40. https:\/\/doi.org\/10.1007\/s00259-011-1988-5.","DOI":"10.1007\/s00259-011-1988-5"},{"key":"7007_CR22","doi-asserted-by":"publisher","unstructured":"Decristoforo C. Gallium-68 - a new opportunity for PET available from a long shelf-life generator - automation and applications. Curr Radiopharm. 2012; 5:212\u2013\u200920. https:\/\/doi.org\/10.2174\/1874471011205030212.","DOI":"10.2174\/1874471011205030212"},{"key":"7007_CR23","doi-asserted-by":"publisher","unstructured":"Zhu W, Zheng G, Yan X, Liu M, Li X, Cheng Y, et al. Diagnostic efficacy of [68Ga]Ga-NY104 PET\/CT to identify clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06801-y.","DOI":"10.1007\/s00259-024-06801-y"},{"key":"7007_CR24","doi-asserted-by":"publisher","unstructured":"van Oostenbrugge TJ, Langenhuijsen JF, Oosterwijk E, Boerman OC, Jenniskens SF,Oyen WJG, et al. Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab. Eur J Nucl Med Mol Imaging. 2020; 47:1864\u20131870. https:\/\/doi.org\/10.1007\/s00259-019-04613-z.","DOI":"10.1007\/s00259-019-04613-z"},{"key":"7007_CR25","doi-asserted-by":"publisher","unstructured":"Civan C, Kuyumcu S, Has Simsek D, Sanli O, Isik EG, Ozkan ZG, et al. The role of [68Ga] Ga-FAPI-04 PET\/CT in renal cell carcinoma: a preliminary study. Eur J Nucl Med Mol Imaging. 2024; 51:852\u2013861. https:\/\/doi.org\/10.1007\/s00259-023-06461-4.","DOI":"10.1007\/s00259-023-06461-4"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-07007-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:55:04Z","timestamp":1739962504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-07007-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7007"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-07007-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Institutional Review Board and Ethical Committee of Harbin Medical University Cancer Hospital and individual consent for this prospective study was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The informed consent form was obtained from each individual for this prospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}